Latest Listings And Ipos News

ARC Funds Limited has secured $600,000 through a share placement priced at a 33% premium to its last traded price, aiming to strengthen its working capital and support growth initiatives.

FortifAI has appointed Kelly Herrell, a seasoned Silicon Valley CEO with a track record of scaling infrastructure tech companies to IPO and acquisition, as its new CEO. Herrell’s leadership aims to accelerate commercialisation of FortifAI’s AI Data Plane technology through its Nol8 subsidiary.

Coda Minerals has secured $6.7 million through an oversubscribed placement to fast-track its Pre-Feasibility Study at Elizabeth Creek, underpinning key technical and environmental programs.

Nova Minerals shareholders and Nasdaq warrantholders overwhelmingly approved schemes to restructure the company under a new US holding entity, pending final court approval.

Theta Gold Mines has locked in a fully subscribed US$90 million senior secured bond to complete the TGME Gold Mine Project in South Africa, targeting first gold production in early 2027.

Findi Limited surged revenue by 36% to $83 million for FY26 but posted a hefty $52.6 million net loss, weighed down by integration costs and capital delays. The company completed a major consolidation of its Indian financial infrastructure assets and secured $25 million in fresh capital to support growth and liquidity.

Evion Group has increased the size of its second tranche placement, lifting total capital raised to A$7.24 million through the issue of over 241 million shares at 3 cents each. The second tranche awaits shareholder approval at a July meeting, including director participation and free attaching options.

IDP Education (ASX:IEL) has responded to an ASX price query following a sharp share price fall and increased trading volume, attributing the movement to a late analyst downgrade and confirming compliance with continuous disclosure rules.

Bass Oil Limited offers up to 24 million free attaching options to recent placement participants, alongside nearly 8 million options to its lead manager PAC Partners, with no new funds raised from the options issue.

Amplia Therapeutics reported encouraging mature data from its ACCENT pancreatic cancer trial showing improved survival and response rates with narmafotinib. The company raised $27.5 million to fund development and manufacturing scale-up, while discontinuing a parallel trial due to chemotherapy toxicity.

Elanor Investors Group has called off its planned acquisition of Singapore-based Firmus Capital due to prolonged regulatory delays, while reaffirming its $125 million recapitalisation with Rockworth Capital Partners and seeking ASX trading reinstatement.

WAM Income Maximiser (ASX: WMX) has outpaced its benchmark with an 18.1% portfolio increase and exceeded its dividend target by delivering a 7.0% fully franked yield in its first year since April 2025.